Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Last trade$5.54
Day change-$0.035 (-0.63%)
Day range$5.42 – $5.75
Volume480,584
Market cap$534M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$534.29M
Price / earnings
—
Price / book
1.99×
Price / sales
0.66×
EV / sales
0.68×
EV / EBITDA
-9.64×
Profitability
Earnings per share
-$1.35
Return on assets
-21.19%
Return on equity
-47.99%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.45×
Current ratio
1.98×
Quick ratio
1.77×
Cash ratio
0.78×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MYGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$202.7M
$190.7M
$200.4M
$209.8M
$205.7M
$213.1M
$195.9M
$210.6M
Cost of revenue
$65M
$63.7M
$62.8M
$63M
$61.9M
$61.3M
$61.7M
$59.7M
Gross profit
$137.7M
$127M
$137.6M
$146.8M
$143.8M
$151.8M
$134.2M
$150.9M
Selling, general and administrative
$151.1M
$140.9M
$135.8M
$124.3M
$138.9M
$138.7M
$135.7M
$136M
Research and development
$26.5M
$25M
$27.1M
$25.5M
$28.2M
$25.6M
$27.5M
$32.2M
Total operating expenses
$177.6M
$165.9M
$168.3M
$152.5M
$167.1M
$481M
$163.2M
$189.9M
Operating income
-$39.9M
-$38.9M
-$30.7M
-$5.7M
-$23.3M
-$329.2M
-$29M
-$39M
Interest expense
-$4.1M
-$4.1M
-$4.1M
-$4.4M
-$3.8M
-$1.5M
-$800K
-$700K
Income before taxes
-$43.6M
-$42.6M
-$34.1M
-$8.9M
-$26.2M
-$330.6M
-$29.4M
-$39.1M
Income taxes
$300K
$600K
$0
-$1M
$1.2M
-$100K
-$29.3M
$3.4M
Net income
-$43.9M
-$43.2M
-$34.1M
-$7.9M
-$27.4M
-$330.5M
-$100K
-$42.5M
Net income attributable to common shareholders
-$43.9M
-$43.2M
-$34.1M
-$7.9M
-$27.4M
-$330.5M
-$100K
-$42.5M
EBITDA
-$27.3M
-$26.4M
-$12.8M
$9.6M
-$10.7M
$1.6M
-$14.6M
$18.8M
Basic earnings per share
-$0.46
-$0.46
-$0.36
-$0.08
-$0.29
-$3.57
$0.00
-$0.47
Diluted earnings per share
-$0.46
-$0.46
-$0.36
-$0.08
-$0.29
-$3.57
$0.00
-$0.47
Recent news
Company coverage with links to the original publishers.
Myriad Genetics (MYGN) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.17 loss, representing a 35.29% earnings surprise. Revenue of $202.7 million exceeded estimates by 7.48%, though down slightly year-over-year. The stock has underperformed the S&P 500 by 12.4% this year. Despite mixed performance, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends, with the Medical - Biomedical and Genetics industry ranking in the top 45% of sectors.
The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.
Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial effective September 16, 2026, replacing departing Chief Commercial Officer Brian Donnelly. Sikri, who previously served as SVP of Product, brings molecular diagnostics and oncology expertise. The company reaffirmed its full-year 2026 financial guidance.
Law firm Bragar Eagel & Squire is investigating Myriad Genetics for potential securities violations following the company's disappointing Q2 2026 earnings report. Myriad reported revenue of $190.7 million, down 11% year-over-year and significantly below consensus estimates. The company slashed full-year 2026 revenue guidance from $860-$880 million to $770-$790 million and suspended EBITDA guidance, citing reimbursement pressure, collection issues, and weak prenatal performance. This represents a dramatic $90 million midpoint cut just three months after reiterating prior guidance in May 2026.
Law firm Kirby McInerney LLP is investigating Myriad Genetics for potential securities fraud following the company's July 30, 2026 earnings report. Myriad reported an 11% year-over-year revenue decline to $190.7 million, reduced full-year guidance, and an $11 million revenue adjustment. Hereditary cancer testing revenue fell 13% despite volume growth, attributed to lower reimbursement and unfavorable estimate changes. Management acknowledged delayed engagement with payers regarding authorization and denial issues. The stock declined 47% to $2.86 on July 31, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.